Skip to main content
SpringerLink
Log in

161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer

  • Review
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Radiotheranostics with 177Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 (161Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of 161Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer. Two clinical trials for 161Tb-PSMA radioligand therapy in prostate cancer are currently underway and will provide valuable insights. This review will shed light on the expanding field of radiotheranostics in prostate cancer, which is not without challenges, and will discuss how the introduction of a new therapeutic option like 161Tb-PSMA may help to combat these challenges and build on the proven success of 177Lu-PSMA-based radiotheranostics for the benefit of prostate cancer patients worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

For this type of study, data sharing is not applicable as no datasets were generated or analyzed.

References

  1. Roy I, Krishnan S, Kabashin AV, Zavestovskaya IN, Prasad PN. Transforming nuclear medicine with nanoradiopharmaceuticals. ACS Nano. 2022;16:5036–61.

    Article  CAS  PubMed  Google Scholar 

  2. Lee DS, Cheon GJ. Nuclear theranostics in Asia: in vivo companion diagnostics. Nucl Med Mol Imaging. 2019;53:1–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hirmas N, Jadaan R, Al-Ibraheem A. Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives. Nucl Med Mol Imaging. 2018;52:190–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mullard A. FDA approves first PSMA-targeted radiopharmaceutical. Nat Rev Drug Discov. 2022;21:327.

    PubMed  Google Scholar 

  6. Luining WI, Cysouw MCF, Meijer D, Hendrikse NH, Boellaard R, Vis AN, et al. Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer. Cancers (Basel). 2022;14:1169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin. 2023; https://doi.org/10.3322/caac.21768.

  8. Ahn BC. Contribution of radionuclide theranostics for managing intractable malignancies. Nucl Med Mol Imaging. 2018;52:168–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al. First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC. J Nucl Med. 2021;62:1391–7.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC. Clin Nucl Med. 2023; https://doi.org/10.1097/RLU.0000000000004589.

  11. Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. (161)Tb-PSMA radioligand therapy: first-in-human SPECT/CT imaging. J Nucl Med. 2023; https://doi.org/10.2967/jnumed.122.265291.

  12. National Cancer Institute. NCI common terminology criteria for adverse events (CTCAE) data files and related documents. National Institutes of Health; 2018. https://evs.nci.nih.gov/ftp1/CTCAE/About.html

    Google Scholar 

  13. Al-Ibraheem A, Mohamedkhair A. Current status of theranostics in Jordan. Nucl Med Mol Imaging. 2019;53:7–10.

    Article  CAS  PubMed  Google Scholar 

  14. Al-Ibraheem A, Abdlkadir A, Albalooshi B, Muhsen H, Haidar M, Omar Y, et al. Theranostics in the Arab World; Achievements & Challenges. Jordan Med J. 2022;56:188–205.

    Google Scholar 

  15. Seitzer KE, Seifert R, Kessel K, Roll W, Schlack K, Boegemann M, et al. Lutetium-177 Labelled PSMA targeted therapy in advanced prostate cancer: current status and future perspectives. Cancers (Basel). 2021;13:3715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Muller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hindié E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759–64.

    Article  PubMed  Google Scholar 

  19. Oh SW, Suh M, Cheon GJ. Current status of PSMA-targeted radioligand therapy in the era of radiopharmaceutical therapy acquiring marketing authorization. Nucl Med Mol Imaging. 2022;56:263–81.

    Article  PubMed  Google Scholar 

  20. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

    Article  CAS  PubMed  Google Scholar 

  21. Bodei L, Herrmann K, Schoder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19:534–50.

    Article  CAS  PubMed  Google Scholar 

  22. Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, et al. Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharm Chem. 2019;4:12.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, et al. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol. 2021;22:e136–e72.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Al-Ibraheem A, Abdlkadir AS, Mohamedkhair A, Mikhail-Lette M, Al-Qudah M, Paez D, et al. Cancer diagnosis in areas of conflict. Front Oncol. 2022;12:1087476.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.

    Article  CAS  PubMed  Google Scholar 

  26. Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F, et al. Development of [(225)Ac]Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC. Pharmaceutics. 2021;13:715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Authors would like to thank the nuclear medicine staff at King Hussein Cancer Center in Amman, Jordan.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), P.O. Box 1269, Al-Jubeiha, Amman, 11941, Jordan

    Akram Al-Ibraheem

  2. Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University of Jordan, Amman, 11942, Jordan

    Akram Al-Ibraheem

  3. Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia

    Andrew M. Scott

  4. Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia

    Andrew M. Scott

  5. School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia

    Andrew M. Scott

  6. Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

    Andrew M. Scott

Authors
  1. Akram Al-Ibraheem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Akram Al-Ibraheem contributed to the conceptualization, design, and writing of this review manuscript. Andrew M. Scott provided critical feedback and revision of the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Akram Al-Ibraheem.

Ethics declarations

Conflict of Interest

Akram Al-Ibraheem and Andrew M. Scott declare no competing interests.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

For this type of study, formal consent is not required and informed consent is not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Ibraheem, A., Scott, A.M. 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. Nucl Med Mol Imaging 57, 168–171 (2023). https://doi.org/10.1007/s13139-023-00804-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-023-00804-7

Keywords

Search

Navigation